Prostate Cancer Reports


Volume 2 Supplement 11
  November 2014

Home > Prostate Cancer Reports > Volume 2 - Year 2014 > Supplement 11, November 2014

CONTENTS



Case reports
Diagnosis and evaluation
Integrative medicine
Overall management
Prognosis and outcome
Treatment


CASE REPORTS



Neuroendocrine prostate cancer

Tagawa ST.
Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle.
J Clin Oncol. 2014 Oct 20;32(30):3360-4. doi: 10.1200/JCO.2014.57.5100. Epub 2014 Sep 15.
Abstract | Related citations

DIAGNOSIS AND EVALUATION



Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, Vollmer C, Droll S, Brunocilla E, Mazzarotto R, Buck AK, Fanti S.
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.
Eur J Nucl Med Mol Imaging. 2014 Aug 15. [Epub ahead of print]
Abstract | Related citations

INTEGRATIVE MEDICINE



Ahmad A, Biersack B, Li Y, Bao B, Kong D, Ali S, Banerjee S, Sarkar FH.
Perspectives on the role of isoflavones in prostate cancer.
AAPS J. 2013 Oct;15(4):991-1000. doi: 10.1208/s12248-013-9507-1. Epub 2013 Jul 4.
Abstract | Full text | Related citations


Carmody J, Olendzki B, Reed G, Andersen V, Rosenzweig P.
A dietary intervention for recurrent prostate cancer after definitive primary treatment: results of a randomized pilot trial.
Urology. 2008 Dec;72(6):1324-8. doi: 10.1016/j.urology.2008.01.015. Epub 2008 Apr 8.
Abstract | Related citations


Chan JM, Gann PH, Giovannucci EL.
Role of diet in prostate cancer development and progression.
J Clin Oncol. 2005 Nov 10;23(32):8152-60.
Abstract | Related citations


Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK.
A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
Prostate Cancer Prostatic Dis. 2014 Sep 23. doi: 10.1038/pcan.2014.37. [Epub ahead of print]
Abstract | Related citations


Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, McTiernan A, Rock CL, Thompson C, Gansler T, Andrews KS; 2006 Nutrition, Physical Activity and Cancer Survivorship Advisory Committee; American Cancer Society.
Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices.
CA Cancer J Clin. 2006 Nov-Dec;56(6):323-53.
Abstract | Full text | Related citations


Hébert JR, Hurley TG, Harmon BE, Heiney S, Hebert CJ, Steck SE.
A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer.
Cancer Epidemiol. 2012 Apr;36(2):e128-36. doi: 10.1016/j.canep.2011.09.008. Epub 2011 Oct 20.
Abstract | Full text | Related citations


Hong MY, Seeram NP, Heber D.
Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.
J Nutr Biochem. 2008 Dec;19(12):848-55. doi: 10.1016/j.jnutbio.2007.11.006. Epub 2008 May 13.
Abstract | Full text | Related citations


Klempner SJ, Bubley G.
Complementary and alternative medicines in prostate cancer: from bench to bedside?
Oncologist. 2012;17(6):830-7. doi: 10.1634/theoncologist.2012-0094. Epub 2012 May 22.
Abstract | Full text | Related citations


Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I, Pelling JC, Bergan RC.
Dietary genistein inhibits metastasis of human prostate cancer in mice.
Cancer Res. 2008 Mar 15;68(6):2024-32. doi: 10.1158/0008-5472.CAN-07-1246.
Abstract | Full text | Related citations


Masko EM, Allott EH, Freedland SJ.
The relationship between nutrition and prostate cancer: is more always better?
Eur Urol. 2013 May;63(5):810-20. doi: 10.1016/j.eururo.2012.11.012. Epub 2012 Nov 15.
Abstract | Full text | Related citations


Miyanaga N, Akaza H, Hinotsu S, Fujioka T, Naito S, Namiki M, Takahashi S, Hirao Y, Horie S, Tsukamoto T, Mori M, Tsuji H.
Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen.
Cancer Sci. 2012 Jan;103(1):125-30. doi: 10.1111/j.1349-7006.2011.02120.x. Epub 2011 Nov 9.
Abstract | Full text | Related citations


Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR.
Intensive lifestyle changes may affect the progression of prostate cancer.
J Urol. 2005 Sep;174(3):1065-9; discussion 1069-70.
Abstract | Full text | Related citations


Pavese JM, Krishna SN, Bergan RC.
Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis.
Am J Clin Nutr. 2014 May 28;100(Supplement 1):431S-436S. [Epub ahead of print]
Abstract | Related citations


Pavese JM, Farmer RL, Bergan RC.
Inhibition of cancer cell invasion and metastasis by genistein.
Cancer Metastasis Rev. 2010 Sep;29(3):465-82. doi: 10.1007/s10555-010-9238-z
Abstract | Full text | Related citations


Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ.
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
BMC Cancer. 2008 May 11;8:132. doi: 10.1186/1471-2407-8-132.
Abstract | Full text | Related citations


Perabo FG, Von Löw EC, Ellinger J, von Rücker A, Müller SC, Bastian PJ.
Soy isoflavone genistein in prevention and treatment of prostate cancer.
Prostate Cancer Prostatic Dis. 2008;11(1):6-12. Epub 2007 Oct 9.
Abstract | Related citations


Posadzki P, Lee MS, Onakpoya I, Lee HW, Ko BS, Ernst E.
Dietary supplements and prostate cancer: a systematic review of double-blind, placebo-controlled randomised clinical trials.
Maturitas. 2013 Jun;75(2):125-30. doi: 10.1016/j.maturitas.2013.03.006. Epub 2013 Apr 6.
Abstract | Full text | Related citations


Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T.
Nutrition and physical activity guidelines for cancer survivors.
CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74. doi: 10.3322/caac.21142. Epub 2012 Apr 26. Review. Erratum in: CA Cancer J Clin. 2013 May;63(3):215.
Abstract | Full text | Erratum | Related citations


Russo M, Spagnuolo C, Tedesco I, Russo GL.
Phytochemicals in cancer prevention and therapy: truth or dare?
Toxins (Basel). 2010 Apr;2(4):517-51. doi: 10.3390/toxins2040517. Epub 2010 Mar 31.
Abstract | Full text | Related citations


Schröder FH, Roobol MJ, Boevé ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, Wildhagen MF, van Helvoort A.
Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Eur Urol. 2005 Dec;48(6):922-30; discussion 930-1. Epub 2005 Oct 17.
Abstract | Related citations


Van Patten CL, de Boer JG, Tomlinson Guns ES.
Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence.
J Urol. 2008 Dec;180(6):2314-21; discussion 2721-2. doi: 10.1016/j.juro.2008.08.078. Epub 2008 Oct 18.
Abstract | Full text | Dare | Related citations

OVERALL MANAGEMENT



Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Bennett CL, Wootton T, Rumble RB, Dusetzina SB, Virgo KS.
Systemic therapy in men with metastatic castration-resistant prostate cancer: american society of clinical oncology and cancer care ontario clinical practice guideline.
J Clin Oncol. 2014 Oct 20;32(30):3436-48. doi: 10.1200/JCO.2013.54.8404. Epub 2014 Sep 8.
Abstract | Full text | Related citations

PROGNOSIS AND OUTCOME



Biochemical recurrence

Chang JH, Park W, Park JS, Pyo H, Huh SJ, Choi HY, Lee HM, Jeon SS, Seo SI
Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.
Int J Urol. 2014 Sep 10. doi: 10.1111/iju.12604. [Epub ahead of print]
Abstract | Related citations


Koo KC, Tuliao P, Komninos C, Choi YD, Chung BH, Hong SJ, Jee SH, Rha KH.
Prognostic Impact of Time to Undetectable Prostate-Specific Antigen in Patients with Positive Surgical Margins Following Radical Prostatectomy.
Ann Surg Oncol. 2014 Sep 5. [Epub ahead of print]
Abstract | Related citations


Michl U, Molfenter F, Graefen M, Tennstedt P, Ahyai S, Beyer B, Budäus L, Haese A, Heinzer H, Oh SJ, Salomon G, Schlomm T, Steuber T, Thederan I, Huland H, Tilki D.
Use of PDE5-inhibitors may adversely impact biochemical recurrence following radical prostatectomy.
J Urol. 2014 Sep 4. pii: S0022-5347(14)04366-3. doi: 10.1016/j.juro.2014.08.111. [Epub ahead of print]
Abstract | Related citations


Simon RM, Freedland SJ, Vidal AC.
Editorial Comment to Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.
Int J Urol. 2014 Sep 10. doi: 10.1111/iju.12621. [Epub ahead of print]
Abstract | Ful text | Related citations


Clinical recurrence

Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ.
Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.
Mod Pathol. 2014 Sep 5. doi: 10.1038/modpathol.2014.116. [Epub ahead of print]
Abstract | Related citations


Neuroendocrine prostate cancer

Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J.
Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis-A Systematic Review and Pooled Analysis.
J Clin Oncol. 2014 Oct 20;32(30):3383-90. doi: 10.1200/JCO.2013.54.3553. Epub 2014 Sep 15.
Abstract | Related citations


From Archives

Bjartell A.
"A robot saved my life": is it a myth?
Eur Urol. 2012 Nov;62(5):775-6; discussion 777-8. doi: 10.1016/j.eururo.2012.06.051. Epub 2012 Jul 7.
Abstract | Full text | Related citations


Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML.
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era.
J Urol. 2010 Mar;183(3):1003-9. doi: 10.1016/j.juro.2009.11.039. Epub 2010 Jan 21.
Abstract | Related citations


Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA.
Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
BJU Int. 2005 Oct;96(6):773-6.
Abstract | Related citations


Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW.
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
J Urol. 2006 Oct;176(4 Pt 1):1404-8.
Abstract | Full text | Related citations


Goldstein MR, Mascitelli L.
Effect of statin use on biochemical outcome following radical prostatectomy.
BJU Int. 2011 Jul;108(2):E6-8; author reply E8. doi: 10.1111/j.1464-410X.2011.10449.x.
Abstract | Full text | Related citations


Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M.
Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
BJU Int. 2010 Jul;106(1):37-43. doi: 10.1111/j.1464-410X.2009.09134.x. Epub 2009 Dec 11.
Abstract | Related citations


Kim KH, Lim SK, Shin TY, Chung BH, Hong SJ, Rha KH.
Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years.
Asian J Androl. 2013 May;15(3):404-8. doi: 10.1038/aja.2013.5. Epub 2013 Mar 25.
Abstract | Full text | Related citations


Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.
Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.
Abstract | Related citations


Min SH, Park YH, Lee SB, Ku JH, Kwak C, Kim HH.
Impact of prostate size on pathologic outcomes and prognosis after radical prostatectomy.
Korean J Urol. 2012 Jul;53(7):463-6. doi: 10.4111/kju.2012.53.7.463. Epub 2012 Jul 19.
Abstract | Full text | Related citations


Ritch CR, Hruby G, Badani KK, Benson MC, McKiernan JM.
Effect of statin use on biochemical outcome following radical prostatectomy.
BJU Int. 2011 Oct;108(8 Pt 2):E211-6. doi: 10.1111/j.1464-410X.2011.10159.x. Epub 2011 Mar 31.
Abstract | Related citations


Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A, Carlsson S, Hosseini A, Adding C, Jonsson M, Ploumidis A, Egevad L, Steineck G, Wiklund P.
Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.
Eur Urol. 2012 Nov;62(5):768-74. doi: 10.1016/j.eururo.2012.05.024. Epub 2012 May 18.
Abstract | Full text | Related citations


Suardi N, Ficarra V, Willemsen P, De Wil P, Gallina A, De Naeyer G, Schatteman P, Montorsi F, Carpentier P, Mottrie A.
Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years.
Urology. 2012 Jan;79(1):133-8. doi: 10.1016/j.urology.2011.08.045. Epub 2011 Nov 16.
Abstract | Related citations

TREATMENT



Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, Delrue L, Billiet I, Duthoy W, Junius S, Huysse W, Lumen N, Ost P.
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
BMC Cancer. 2014 Sep 15;14:671. doi: 10.1186/1471-2407-14-671.
Abstract | Full text | Related citations


Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, Karakiewicz P, Guazzoni G, Montorsi F, Briganti A, Menon M, Abdollah F.
Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study.
Eur Urol. 2014 Sep 9. pii: S0302-2838(14)00809-4. doi: 10.1016/j.eururo.2014.08.056. [Epub ahead of print]
Abstract | Related citations


Klein EA.
Seeing and Not Believing: Oligometastases and the Future of Metastatic Prostate Cancer.
Eur Urol. 2014 Oct 10. pii: S0302-2838(14)00972-5. doi: 10.1016/j.eururo.2014.09.035. [Epub ahead of print]
Abstract | Related citations


Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A.
Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature.
Eur Urol. 2014 Sep 17. pii: S0302-2838(14)00889-6. doi: 10.1016/j.eururo.2014.09.004. [Epub ahead of print]
Abstract | Related citations


Schmidt C.
Hormone therapy can wait in PSA-only relapse.
J Natl Cancer Inst. 2014 Aug 13;106(8). pii: dju278. doi: 10.1093/jnci/dju278. Print 2014 Aug.
Abstract | Full text | Related citations


Schwarz R, Graefen M, Krüll A.
Therapy of recurrent disease after radical prostatectomy in 2007.
World J Urol. 2007 Apr;25(2):161-7. Epub 2007 Feb 28.
Abstract |
Related citations



Schwarz R, Graefen M, Kru A.
Therapy of Treatment Failure After Curative Treatment of Prostate Cancer
EAU-EBU Update Series, Volume 4, Issue 6, December 2006, Pages 228–240
Abstract | Full text | Related citations


Zilli T, Miralbell R.
Editorial Comment from Dr Zilli and Dr Miralbell to Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria.
Int J Urol. 2014 Sep 4. doi: 10.1111/iju.12614. [Epub ahead of print]
Abstract | Full text | Related citations